Multiple Antioxidants in the Prevention and Treatment of Alzheimer Disease: Analysis of Biologic Rationale
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The etiology of Alzheimer disease (AD) is not well understood; therefore, neither prevention strategies nor long-term effective treatment modalities are available for this disease. Based on laboratory and clinical studies, it appears that reactive oxygen species (ROS) and reactive nitrogen species (RNS) that are generated extracellularly and intracellularly by various mechanisms are among the major intermediary risk factors that initiate and promote neurodegeneration in idiopathic AD. Therefore, multiple antioxidant supplements could be useful in the prevention of AD, and as an adjunct to standard therapy in the treatment of AD. The products of inflammatory reactions such as prostaglandins (PGs; PGE1 and PGA1), free radicals, cytokines, and complement proteins are neurotoxic. Nonsteroidal antiinflammatory drugs (NSAIDs), which inhibit the synthesis of PGs, reduce the rate of deterioration of cognitive functions in patients with advanced AD. Cholinergic drugs are routinely used in the treatment of AD to improve cognitive functions. Therefore, we propose that a combination of multiple antioxidants and NSAIDs may be more beneficial in the prevention of AD, and that this combination taken together with cholinergic drugs may be more effective in the treatment of AD than the individual agents alone. We also hypothesize that, in idiopathic AD, epigenetic components of neurons such as mitochondria, membranes, other membranous structures, and protein modifications--rather than the genes of neurons--are the primary targets for the action of neurotoxins including free radicals. In some familial AD, mutations in amyloid precursor protein and presenilins are associated with the risk of early onset of this disease; however, their mechanisms of action are not fully understood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 3×
“Indeed, a controlled clinical trial with dl- tocopherol (synthetic form; 2,000 IU/d) in patients with moderately severe impairment from AD showed some beneficial effects with respect to rate of deterioration of cognitive function (87).”
BackgroundResultInfluentialHydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 1×
“Therefore, these products may represent extracellular signals that initiate neuronal degeneration in AD via several intracellular signals including -amyloid (7–10), ubiquitin (12,13), and presenilins (PS) I and II (11,32,33).”
BackgroundNeurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state
Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
Lorenzo, A., & Yankner, B. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12243 · Cited by 1,324
Evans, D. A. (1989) · JAMA · doi:10.1001/jama.1989.03430180093036 · Cited by 1,226
Harman, D. (1992) · Mutation Research/DNAging · doi:10.1016/0921-8734(92)90030-s · Cited by 902
Brain cytochrome oxidase in Alzheimer's disease
Kish, S. J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L., Wilson, J. M., DiStefano, L. M., & Nobrega, J. N. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09439.x · Cited by 537 · cited 1×
“For example, decreased glucose uptake coupled with reduced activity of cytochrome oxidase (complex IV) leads to increased production of ROS by mitochondria (40,41).”
BackgroundImmunoglobulins and complement factors in senile plaques: An immunoperoxidase study
Eikelenboom, P., & Stam, F. C. (1982) · Acta Neuropathologica · doi:10.1007/bf00685397 · Cited by 454
Cited by
Nanoparticles in cellular drug delivery
Faraji, A. H., & Wipf, P. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.02.043 · Cited by 903
Alzheimer’s disease pathogenesis and therapeutic interventions
Parihar, M. S., & Hemnani, T. (2004) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2003.12.007 · Cited by 433
Behl, C., & Moosmann, B. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00883-3 · Cited by 302
Achieving and Maintaining Cognitive Vitality With Aging
Fillit, H. M., Butler, R. N., O'Connell, A. W., Albert, M. S., Birren, J. E., Cotman, C. W., Greenough, W. T., Gold, P. E., Kramer, A. F., Kuller, L. H., et al. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.7.681 · Cited by 300
Hayashi, M., Kim, S.-W., Imanaka-Yoshida, K., Yoshida, T., Abel, E. D., Eliceiri, B., Yang, Y., Ulevitch, R. J., & Lee, J.-D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19890 · Cited by 277
Metadata
- Authors
- Prasad, K. N., Hovland, A. R., Cole, W. C., Prasad, K. C., Nahreini, P., Edwards-Prasad, J., & Andreatta, C. P.
- Venue
- Clinical Neuropharmacology
- Published
- 2000-01
- Volume
- 23
- Issue
- 1
- Pages
- 2-13
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2075482140
- Cited by
- 74
- References
- 18
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiple Antioxidants in the Prevention and Treatment of Alzheimer Disease: Analysis of Biologic Rationale. https://app.cochat.ai/papers/10.1097/00002826-200001000-00002
- The paper
- Prasad, K. N., Hovland, A. R., Cole, W. C., Prasad, K. C., Nahreini, P., Edwards-Prasad, J., & Andreatta, C. P. (2000). Multiple Antioxidants in the Prevention and Treatment of Alzheimer Disease: Analysis of Biologic Rationale. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-200001000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.